Boehringer Ingelheim loses patent battle with India’s Cipla

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Boehringer Ingelheim loses patent battle with India’s Cipla

INICIO/Noticias Farmacéuticas | Posted 20/03/2015 0 Post your comment

German pharmaceutical company Boehringer Ingelheim (Boehringer) has lost its patent on the Spiriva respiratory drug in India. The Indian patent office has agreed with the Indian drugmaker Cipla that Boehringer’s Spiriva patent was obvious and was not an invention under India’s patent laws.

Cipla, India's fourth-largest drugmaker by sales, filed its opposition to Boehringer's patent on Spiriva in 2013.

Boehringer is the latest in a growing list of Western drug companies coming up against the Indian patent office in favour of India-based generics companies.

In 2012, German drugmaker Bayer lost its appeal against the Indian Government’s decision to grant a compulsory licence for its cancer drug Nexavar (sorafenib). India issued a compulsory licence to India-based generics firm Natco Pharma enabling them to produce generics of Nexavar, claiming the price made it unaffordable for many patients [1].

In the same year, Novartis challenged India for denying it a patent for Glivec (imatinib mesylate), its blockbuster cancer drug [2]. Other cases that have come before the Indian courts include Roche’s attempt to protect its lung cancer drug Tarceva (erlotinib). The Indian court upheld Roche’s patent for Tarceva, but said that Cipla’s generic version, Erlocip, did not infringe on Roche’s patent as the molecular structure of Cipla’s generic version was different to that of Roche’s drug [2].

The Indian Government has issued several compulsory licences for patented drugs to Indian drugmakers, allowing local companies to launch generic versions of the drugs before the patents expire on the originator drugs. The idea behind compulsory licensing is to provide low cost medicines and increase access to medicines for poorer people in a public health crisis [3].

Following the Spiriva decision, a spokeswoman at Boehringer's India office said that the company will be ‘evaluating carefully the basis for the recent decision once the detailed reasons thereof are available.’

Related articles
Generics makers challenging more patents

Cipla petitions Indian government to revoke Onbrez patents

Roche wins case against Herceptin ‘similar biologics’ producers

References
1. GaBI Online - Generics and Biosimilars Initiative. Bayer loses Nexavar compulsory licence appeal [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Mar 20]. Available from: www.gabionline.net/Generics/News/Bayer-loses-Nexavar-compulsory-licence-appeal
2. GaBI Online - Generics and Biosimilars Initiative. India issues more compulsory licences [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Mar 20]. Available from: www.gabi-journal.net/news/india-issues-more-compulsory-licences
3. GaBI Online - Generics and Biosimilars Initiative. India’s patent laws coming under repeated challenges [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Mar 20]. Available from: www.gabionline.net/Policies-Legislation/India-s-patent-laws-coming-under-repeated-challenges

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.